Rhythm Pharmaceuticals (RYTM) Set to Announce Quarterly Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) is set to release its earnings data before the market opens on Tuesday, May 7th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($2.12) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.70) EPS for the quarter, meeting the consensus estimate of ($0.70). The company had revenue of $24.23 million during the quarter, compared to analysts’ expectations of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative return on equity of 96.02%. The firm’s revenue was up 175.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.75) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock traded up $1.25 during trading on Tuesday, hitting $40.07. 140,490 shares of the stock were exchanged, compared to its average volume of 611,404. The firm’s 50-day moving average price is $41.39 and its 200 day moving average price is $39.08. Rhythm Pharmaceuticals has a 12-month low of $15.50 and a 12-month high of $52.57.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 71,774 shares of Rhythm Pharmaceuticals stock in a transaction on Friday, February 9th. The shares were sold at an average price of $50.38, for a total value of $3,615,974.12. Following the transaction, the insider now directly owns 2,686 shares in the company, valued at $135,320.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Yann Mazabraud sold 1,594 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $51.38, for a total transaction of $81,899.72. Following the transaction, the executive vice president now directly owns 7,702 shares in the company, valued at $395,728.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph Shulman sold 71,774 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $50.38, for a total transaction of $3,615,974.12. Following the transaction, the insider now owns 2,686 shares in the company, valued at $135,320.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 172,069 shares of company stock worth $7,626,355. 4.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RYTM shares. Wells Fargo & Company decreased their price objective on shares of Rhythm Pharmaceuticals from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Thursday, April 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Friday. Finally, The Goldman Sachs Group boosted their price target on shares of Rhythm Pharmaceuticals from $42.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $47.20.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.